Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Best Available Therapy Clear all
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Not applicable Interventional Results available

Bright Start Study

NCT05356130
View directory record Official record
Conditions
Depression
Interventions
Written Educational Material on BLT, Enhanced BLT Encouragement and Adherence Promotion
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 24, 2026, 11:27 AM EDT
Active, not recruiting Not applicable Interventional

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

NCT03913481
View directory record Official record
Conditions
C.Surgical Procedure; Cardiac
Interventions
Acute normovolemic hemodilution, Standard care
Procedure
Lead sponsor
Università Vita-Salute San Raffaele
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Early Phase 1 Interventional

Convalescent Plasma in Pediatric COVID-19

NCT04458363
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma (CP), Standard COVID-19 therapies
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
0 Years to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 24, 2026, 11:27 AM EDT
Withdrawn Phase 2 Interventional

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
View directory record Official record
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 24, 2026, 11:27 AM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 24, 2026, 11:27 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma

NCT03986502
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Media Intervention, Informational Intervention, Best Practice, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

NCT05480228
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
NRD135SE.1, Placebo
Drug · Other
Lead sponsor
James P. Rathmell, MD
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
San Diego, California • Clermont, Florida • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 3 Interventional

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

NCT04935177
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
Drug · Procedure · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 24, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, Observation, GM-CSF, Montanide
Biological · Drug · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944
View directory record Official record
Conditions
Polycythemia Vera
Interventions
ruxolitinib tablets, Best Available Therapy (BAT)
Drug · Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 24, 2026, 11:27 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

NCT02300558
View directory record Official record
Conditions
Long QT Syndrome Type 3
Interventions
Eleclazine, Eleclazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Not applicable Interventional

TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)

NCT02413216
View directory record Official record
Conditions
Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
Interventions
TicHelper, Internet Based Resources
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
8 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Salt Lake City, Utah • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 24, 2026, 11:27 AM EDT
Recruiting Not applicable Interventional

Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care

NCT05869552
View directory record Official record
Conditions
Suicide, Suicidal Ideation
Interventions
STAT-PC, YST-III
Other
Lead sponsor
Elizabeth Arnold
Other
Eligibility
18 Years to 24 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 1 Interventional

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

NCT03232424
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT)
Device · Drug · Radiation
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 24, 2026, 11:27 AM EDT
Completed No phase listed Observational

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

NCT05421104
View directory record Official record
Conditions
Polycythemia Vera (PV)
Interventions
Ruxolitinib
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department

NCT02899065
View directory record Official record
Conditions
Influenza, Human
Interventions
Procalcitonin, Pharmacist-Led Education
Diagnostic Test · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 49 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 24, 2026, 11:27 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Phase 4 Interventional

The Kentucky Viral Hepatitis Treatment Study

NCT03949764
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions
Sofosbuvir/velpatasvir (Epclusa®)
Drug
Lead sponsor
Jennifer Havens
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 24, 2026, 11:27 AM EDT
Completed Not applicable Interventional Results available

Financial Incentives for Smoking Cessation Among Mothers

NCT05740098
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Best Practices, Financial Incentives, Nicotine Replacement Therapy
Behavioral · Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 24, 2026, 11:27 AM EDT
Not listed No phase listed Observational

The Global cVAD Study

NCT04136392
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
ABIOMED, Inc. hemodynamic support devices
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 24, 2026, 11:27 AM EDT
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 24, 2026, 11:27 AM EDT